CA2624110A1 - A rapidly-dissolving orally administrable wafer formulation - Google Patents
A rapidly-dissolving orally administrable wafer formulation Download PDFInfo
- Publication number
- CA2624110A1 CA2624110A1 CA 2624110 CA2624110A CA2624110A1 CA 2624110 A1 CA2624110 A1 CA 2624110A1 CA 2624110 CA2624110 CA 2624110 CA 2624110 A CA2624110 A CA 2624110A CA 2624110 A1 CA2624110 A1 CA 2624110A1
- Authority
- CA
- Canada
- Prior art keywords
- wafer
- agent
- gel
- film forming
- pharmaceutical agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims 2
- 238000009472 formulation Methods 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims abstract 16
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract 14
- 238000010438 heat treatment Methods 0.000 claims abstract 9
- 239000007864 aqueous solution Substances 0.000 claims abstract 6
- 238000001816 cooling Methods 0.000 claims abstract 6
- 238000000034 method Methods 0.000 claims 11
- 238000004090 dissolution Methods 0.000 claims 3
- 229920001685 Amylomaize Polymers 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- 229920002125 Sokalan® Polymers 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 2
- -1 metophon Chemical compound 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
- 229920000856 Amylose Polymers 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 claims 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000004373 Pullulan Substances 0.000 claims 1
- 229920001218 Pullulan Polymers 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000002269 analeptic agent Substances 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 229920001525 carrageenan Polymers 0.000 claims 1
- 229940113118 carrageenan Drugs 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000002826 coolant Substances 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 229960002428 fentanyl Drugs 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 1
- 229960000240 hydrocodone Drugs 0.000 claims 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 1
- 229960001410 hydromorphone Drugs 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 claims 1
- 229960003406 levorphanol Drugs 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 229960000938 nalorphine Drugs 0.000 claims 1
- 229960004127 naloxone Drugs 0.000 claims 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 1
- 229960003086 naltrexone Drugs 0.000 claims 1
- 229960005118 oxymorphone Drugs 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 239000004584 polyacrylic acid Substances 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 235000019423 pullulan Nutrition 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 229940005550 sodium alginate Drugs 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
An orally administrable wafer is provided comprising at least one physiologically acceptable film forming agent. The wafer is formed by mixing the film-forming agent with an aqueous solution to form a gel and exposing the gel to a plurality of heating and cooling cycles. The wafer is rapidly dissolving and suitable for administration of pharmaceutical agents.
Claims (24)
1. An orally administrable wafer comprising at least one physiologically acceptable film forming agent, wherein the film forming agent is dissolved in an aqueous solution and treated with heat to form a wafer that exhibits a dissolution rate of at least about 2 milligrams/sec in an aqueous environment.
2. A wafer as defined in claim 1, wherein the film forming agent is selected from the group consisting of pullulan, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, glycolide, polylactide, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl polymer, amylose, high amylose starch, hydroxypropylated high amylose starch, dextrin, pectin, chitin, chitosan, levan, elsinan and mixtures thereof.
3. A wafer as defined in claim 2, comprising the film forming agents pullalan, PEG, polyvinyl alcohol and carrageenan.
4. A wafer as defined in claim 1, additionally comprising a pharmaceutical agent.
5. A wafer as defined in claim 4, wherein the pharmaceutical agent is an analgesic.
6. A wafer as defined in claim 5, wherein the pharmaceutical agent is selected from the group consisting of morphine, heroin, hydromorphone, metophon, oxymorphone, levorphanol, codeine, hydrocodone, xycodone, nalorphine, naloxone, naltrexone and fentanyl.
7. A wafer as defined in claim 4, wherein the pharmaceutical agent is an anti-microbial agent.
8. A wafer as defined in claim 1, additionally comprising one or more compounds selected from the group consisting of: a plasticizing agent, a flavoring agent, a sulfur precipitating agent, a saliva stimulating agent, a cooling agent, a surfactant, a stabilizing agent, an emulsifying agent, a thickening agent, a binding agents, a coloring agent, a sweetener, and a fragrance.
9. An orally administrable wafer comprising at least one physiologically acceptable film forming agent, wherein said wafer is formed by mixing the film forming agent with an aqueous solution to form a gel and exposing the gel to a plurality of heating and cooling cycles.
10. A wafer as defined in claim 4, that exhibits a T max, of the agent on administration of the wafer to a patient of less than about 7 minutes.
11. A method of preparing an orally administrable wafer comprising the steps of:
1) mixing at least one physiologically acceptable film forming agent with an aqueous solution to form a gel; and 2) exposing the gel to a plurality of cycles, each cycle comprising heating and cooling, to transform the gel into a wafer.
1) mixing at least one physiologically acceptable film forming agent with an aqueous solution to form a gel; and 2) exposing the gel to a plurality of cycles, each cycle comprising heating and cooling, to transform the gel into a wafer.
12. A method as defined in claim 11, wherein each cycle comprises a period of heating up to a temperature within the range of 60 - 90 °C.
13. A method as defined in claim 11, wherein each cycle comprises a period of heating and a period of cooling, and each of said periods lasts about 5 - 15 s.
14. A method as defined in claim 11, comprising at least 3 cycles of heating and cooling.
15. A method as defined in claim 14, wherein the total time of the cycles is between about 1 and 2 minutes.
16. A method as defined in claim 11, comprising the additional step of adding a pharmaceutical agent dissolved in an aqueous solution to the gel prior to heating.
17. A method as defined in claim 16, wherein a measured amount of pharmaceutical agent is added to the gel to yield a wafer with a defined quantity of pharmaceutical agent therein.
18. A method as defined in claim 11, wherein the heating is achieved by exposure to microwaves.
19. An orally administrable wafer comprising a pharmaceutical agent and at least one physiologically acceptable film forming agent, wherein the pharmaceutical agent is present in a pre-defined quantity.
20. A wafer as defined in claim 19, having a dissolution rate of at least about 2 milligrams/sec in an aqueous environment.
21. A wafer as defined in claim 4, wherein the C max of the agent attained on administration of the wafer to a patient is at least about 25%.
22. A method of administering a pharmaceutical agent to a mammal comprising the step of orally administering to the mammal a wafer comprising the pharmaceutical agent, wherein said wafer comprises at least one physiologically acceptable film forming agent and the pharmaceutical agent and the wafer is characterized by a dissolution rate of at least about 2 mg/s in an aqueous environment.
23. A method as defined in claim 22, wherein the pharmaceutical agent treats pain.
24. A method as defined in claim 22, wherein the wafer is prepared by mixing at least one physiologically acceptable film forming agent with an aqueous solution to form a gel;
and exposing the gel to a plurality of cycles, each cycle comprising heating and cooling, to transform the gel into a wafer.
and exposing the gel to a plurality of cycles, each cycle comprising heating and cooling, to transform the gel into a wafer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2624110A CA2624110C (en) | 2008-03-27 | 2008-03-27 | A rapidly-dissolving orally administrable wafer formulation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2624110A CA2624110C (en) | 2008-03-27 | 2008-03-27 | A rapidly-dissolving orally administrable wafer formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2624110A1 true CA2624110A1 (en) | 2008-11-14 |
| CA2624110C CA2624110C (en) | 2010-11-09 |
Family
ID=39971178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2624110A Active CA2624110C (en) | 2008-03-27 | 2008-03-27 | A rapidly-dissolving orally administrable wafer formulation |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2624110C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11166912B2 (en) | 2016-03-03 | 2021-11-09 | Ctt Pharma Inc. | Orally administrable composition |
| US11298336B2 (en) | 2019-05-30 | 2022-04-12 | Soluble Technologies, Inc. | Water soluble formulation |
| US11786475B2 (en) | 2020-07-22 | 2023-10-17 | Soluble Technologies Inc. | Film-based dosage form |
-
2008
- 2008-03-27 CA CA2624110A patent/CA2624110C/en active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11166912B2 (en) | 2016-03-03 | 2021-11-09 | Ctt Pharma Inc. | Orally administrable composition |
| US11298336B2 (en) | 2019-05-30 | 2022-04-12 | Soluble Technologies, Inc. | Water soluble formulation |
| US11786475B2 (en) | 2020-07-22 | 2023-10-17 | Soluble Technologies Inc. | Film-based dosage form |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2624110C (en) | 2010-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018388577B2 (en) | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | |
| JP6254148B2 (en) | Oral film containing opiate enteric-release beads | |
| JP5723787B2 (en) | Controlled release formulation or food formulation and method for producing the same | |
| CA3097737A1 (en) | Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system | |
| CN107441067A (en) | For transmitting the anti-abuse mucomembranous adhesion agent device of buprenorphine | |
| MXPA06002022A (en) | Edible film for relief of cough or symptoms associated with pharyngitis. | |
| FR2960775A1 (en) | MICROGRANULES RESISTANT TO MISMATCH | |
| CN113908153B (en) | Buvaracetam pharmaceutical composition, preparation method and application thereof | |
| EP3137062A1 (en) | Monolithic tablets based on carboxyl polymeric complexes for controlled drug release | |
| JP2010518086A5 (en) | ||
| JPWO2006082842A1 (en) | Hard capsule with improved solubility | |
| KR20080048461A (en) | Gastrointestinal retention agent and preparation method thereof | |
| Garg et al. | Applications of natural polymers in mucoadhesive drug delivery: An overview | |
| TW200900096A (en) | Tablet coatings made from modified carboxymethylcellulose materials | |
| CA2624110A1 (en) | A rapidly-dissolving orally administrable wafer formulation | |
| AU2012390362B2 (en) | Oral preparation and method for producing the same | |
| US20130216594A1 (en) | Preparation of orodispersible films | |
| CN105012276A (en) | Imidafenacin oral fast dissolving film and preparation method and application thereof | |
| WO2024220974A1 (en) | Rimegepant fast-dissolving films for oral administration | |
| TR202016210A2 (en) | Pharmaceutical form containing acidic substance | |
| CN104940173A (en) | Soluble fentanyl, derivative buccal membrane preparation thereof and preparing method thereof | |
| Shivashankar et al. | Formulation and evaluation of bupivacaine-loaded glutaraldehyde-crosslinked high molecular weight chitosan microspheres | |
| CN104146979A (en) | Pramipexole dihydrochloride sustained release tablet and preparation method thereof | |
| Mishra et al. | Development and in vitro evaluation of hydrophilic matrix tablets of diltiazem hydrochloride | |
| CN106109400A (en) | A kind of oral drugs hydrogel slow-released carrier and preparation method and applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |